Authors
Irvin M Modlin, Kjell Oberg, Daniel C Chung, Robert T Jensen, Wouter W De Herder, Rajesh V Thakker, Martyn Caplin, Gianfranco Delle Fave, Greg A Kaltsas, Eric P Krenning, Steven F Moss, Ola Nilsson, Guido Rindi, Ramon Salazar, Philippe Ruszniewski, Anders Sundin
Publication date
2008/1/1
Source
The lancet oncology
Volume
9
Issue
1
Pages
61-72
Publisher
Elsevier
Description
Gastroenteropancreatic (GEP) neuroendocrine tumours (NETs) are fairly rare neoplasms that present many clinical challenges. They secrete peptides and neuroamines that cause distinct clinical syndromes, including carcinoid syndrome. However, many are clinically silent until late presentation with mass effects. Investigation and management should be highly individualised for a patient, taking into consideration the likely natural history of the tumour and general health of the patient. Management strategies include surgery for cure (which is achieved rarely) or for cytoreduction, radiological intervention (by chemoembolisation and radiofrequency ablation), chemotherapy, and somatostatin analogues to control symptoms that result from release of peptides and neuroamines. New biological agents and somatostatin-tagged radionuclides are under investigation. The complexity, heterogeneity, and rarity of GEP NETs …
Total citations
Scholar articles
IM Modlin, K Oberg, DC Chung, RT Jensen… - The lancet oncology, 2008